JW Pharmaceutical Corp (001065) — Free Cash Flow Generation Index

Latest as of June 2026: 0.89x

JW Pharmaceutical Corp (001065) has a Free Cash Flow Generation Index of 0.89x as of June 2026. Free cash flow of ₩37.98 Billion represents 1% of operating cash flow (₩42.51 Billion). Explore JW Pharmaceutical Corp (001065) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.

FCF Generation Index

0.89x
Free Cash Flow / Operating CF

Free Cash Flow

₩37.98 Billion
KRW

Operating Cash Flow

₩42.51 Billion
KRW

Capital Expenditures

₩4.52 Billion
KRW

JW Pharmaceutical Corp Free Cash Flow Generation Index (2014–2025)

Historical FCF Generation Index trend for JW Pharmaceutical Corp across 11 annual periods. For the full cash flow conversion analysis, see JW Pharmaceutical Corp cash conversion from operations.

Annual Free Cash Flow Generation for JW Pharmaceutical Corp (2014–2025)

Year-by-year Free Cash Flow Generation Index for JW Pharmaceutical Corp. Check how aggressively does JW Pharmaceutical Corp reinvest cash to assess the company's total reinvestment commitment from operating cash flow.

Year FCG Index Free Cash Flow (KRW) Operating CF Capital Expenditures YoY Change
2025 0.63x ₩60.28 Billion ₩96.40 Billion ₩36.12 Billion ▼ -3.1%
2024 0.65x ₩51.25 Billion ₩79.39 Billion ₩28.14 Billion ▲ +21.1%
2023 0.53x ₩46.45 Billion ₩87.16 Billion ₩40.71 Billion ▼ -31.9%
2022 0.78x ₩44.41 Billion ₩56.76 Billion ₩9.92 Billion ▲ +171.5%
2021 0.29x ₩5.22 Billion ₩18.12 Billion ₩7.47 Billion ▼ -62.2%
2020 0.76x ₩48.02 Billion ₩63.05 Billion ₩12.39 Billion ▼ -0.3%
2019 0.76x ₩42.43 Billion ₩55.53 Billion ₩9.28 Billion ▼ -9.0%
2018 0.84x ₩43.76 Billion ₩52.11 Billion ₩8.64 Billion ▲ +24.9%
2017 0.67x ₩22.50 Billion ₩33.45 Billion ₩7.50 Billion ▼ -73.0%
2016 2.49x ₩16.76 Billion ₩6.74 Billion ₩10.02 Billion ▲ +27.4%
2014 1.95x ₩14.21 Billion ₩7.28 Billion ₩6.93 Billion
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).